Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof wherein: Q is: (i) 5 membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg or (ii) 9 to 10 membered bicyclic heteroaryl selected from Formula (II) and wherein Ring A is a 5 to 6 membered aryl or heteroaryl fused ring substituted with zero to 2 Rg and R1 R2 R3 and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition such as for example cancer and pharmaceutical compositions comprising such compounds.
